The Future Of OTCs: Self-Selection Meets Diagnostics, Genetic Personalization
This article was originally published in The Tan Sheet
Executive Summary
The next generation of consumer health products, including Rx-to-OTC switch opportunities, may work in concert with cutting-edge diagnostic tools and elements of personalized medicine, says Andrew Fish.
You may also be interested in...
FDA's OTC Naloxone Study Is A Starting Point For Other Switches, Not A Roadmap
CDER has been studying ideas such as pictograms to communicate instructions on administering opioid-reversal medication, but officials can’t predict when new approaches might help enable FDA to propose regulatory changes in the US switch process.
FDA's OTC Naloxone Study Is A Starting Point For Other Switches, Not A Roadmap
CDER has been studying ideas such as pictograms to communicate instructions on administering opioid-reversal medication, but officials can’t predict when new approaches might help enable FDA to propose regulatory changes in the US switch process.
CHPA Product Quality & Operations Workshop In Brief
Facilitating switch is CHPA’s top priority